Mirum Pharmaceuticals Inc MIRM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
-
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
-
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
-
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $85.48
- Day Range
- $83.68–86.17
- 52-Week Range
- $63.23–130.00
- Bid/Ask
- $83.55 / $83.96
- Shares Outstanding
- 64.93M
- Market Cap
- $5.45B
- Volume/Avg
- 641,935 / 682,217
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 433
- Website
- https://www.mirumpharma.com
Valuation
|
Metric
|
MIRM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 7.62 |
Price/Cash Flow | — |
Price/Earnings
MIRM
Financial Strength
|
Metric
|
MIRM
|
|---|---|
Quick Ratio | 2.62 |
Current Ratio | 2.86 |
Interest Coverage | −63.85 |
Quick Ratio
MIRM
Profitability
|
Metric
|
MIRM
|
|---|---|
Return on Assets (Normalized) | −22.16% |
Return on Equity (Normalized) | −86.90% |
Return on Invested Capital (Normalized) | −30.36% |
Return on Assets
MIRM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|M<Nq!< | LOCK|S^$& | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|zKB$xg | LOCK|^gm> | $76B | |||
| Moderna Inc
MRNA
| LOCK|Z!?P<@# | LOCK|m<# | $75B | |||
| argenx SE ADR
ARGX
| LOCK|d^TL?H | LOCK|>> | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$C<WTM | LOCK|Wt | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|PYYn&Y | LOCK|^Fgp& | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|KcVm!L$ | LOCK|C?kK$ | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|w<>q#YZ | LOCK|&Z> | $24B | |||
| Incyte Corp
INCY
| LOCK|D%g?JZ | LOCK|w%& | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|s?JfC$< | LOCK|!^ | $15B |
United States